Impact of Different Dialysis on Sleep Apnea in Patients With Renal Failure
Launched by MCGILL UNIVERSITY HEALTH CENTRE/RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE · Sep 25, 2006
Trial Information
Current as of August 02, 2025
Unknown status
Keywords
ClinConnect Summary
Sleep apnea or breathing problems during sleep are frequent, occurring in 6% of the general population. However, more than half of all patients on dialysis suffer from breathing problems related to sleep. Sleep apnea is associated with high blood pressure, excessive sleepiness, fatigue, poor memory and concentration as well as depression in those with normal kidneys.
Hemodiafiltration is a new kind of dialysis that is more efficient at clearing toxins that accumulate in kidney failure. It has been used successfully in Europe for over 15 years. However, the effects of hemodiafiltration on s...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients currently stable on a thrice weekly hemodialysis regimen for a minimum of 3 months
- • Patients with vascular access and no contraindications to anticoagulation
- • Presence of sleep-related breathing disorder defined as a mean apnea-hypopnea per hour of recording greater than 10 based on cardiorespiratory monitoring
- Exclusion Criteria:
- • Patients already on hemodiafiltration therapy
- • Patients already on treatment for sleep disordered breathing.
- • Patients with significant neuromuscular disease
- • Patients with an expected lifespan \< 1 year
- • Patients unable to complete sleep related quality of life questionnaires and consent forms due to language barriers or dementia
- • Patients with known substance abuse
- • Patients with a respiratory disturbance index greater than 30 with active cardiovascular disease defined by unstable angina, myocardial infarction within 3 months or an Epworth sleepiness score greater than 15 while actively working in a stress situation (for example bus driver, taxi driver). These patients will be evaluated by a sleep specialist.
- • Living further than 30 km from dialysis centre
About Mcgill University Health Centre/Research Institute Of The Mcgill University Health Centre
The McGill University Health Centre (MUHC) and the Research Institute of the McGill University Health Centre (RI-MUHC) are leading institutions in clinical research and healthcare innovation. With a commitment to advancing medical knowledge and improving patient outcomes, the MUHC integrates cutting-edge research with high-quality patient care. The RI-MUHC fosters a collaborative environment where multidisciplinary teams engage in transformative research across various fields, including oncology, neurology, and cardiovascular health. By leveraging state-of-the-art facilities and a robust network of clinical expertise, both entities strive to translate scientific discoveries into effective treatments, ultimately enhancing the quality of life for patients locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montreal, Quebec, Canada
Patients applied
Trial Officials
Kateri A Champagne, M.D.
Principal Investigator
McGill University Health Centre/Research Institute of the McGill University Health Centre
Navdeep Tangri, M.D.
Principal Investigator
McGill University
John R Kimoff, M.D.
Principal Investigator
McGill University Health Centre/Research Institute of the McGill University Health Centre
Paul Barre, M.D.
Principal Investigator
McGill University Health Centre/Research Institute of the McGill University Health Centre
Sameena Iqbal, M.D.
Principal Investigator
McGill University Health Centre/Research Institute of the McGill University Health Centre
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials